NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$15.31
$15.31
50-Day Range
$15.31
$15.45
52-Week Range
$4.75
$16.10
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50

Icosavax MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
73.1% Upside
$26.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$229,350 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.20) to ($2.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

Medical Sector

777th out of 910 stocks

Biotechnology Industry

8th out of 15 stocks

ICVX stock logo

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

ICVX Stock News Headlines

NervGen Pharma Corp Ordinary Shares NGEN
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Icosavax: Tender Offer With Contingent Value Right
Icosavax CVR Seems Fairly Valued
Guggenheim Downgrades Icosavax (ICVX)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
ICVX Jul 2024 15.000 call
Icosavax just downgraded at Jefferies, here's why
Icosavax just downgraded at William Blair, here's why
See More Headlines
Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.50
High Stock Price Target
$28.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+73.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$5.47 per share

Miscellaneous

Free Float
34,767,000
Market Cap
$766.88 million
Optionable
Optionable
Beta
1.28
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Adam K. Simpson (Age 48)
    President, CEO, Co-Founder & Director
    Comp: $855.95k
  • Mr. Niranjan Kanesa-thasan M.D. (Age 63)
    Chief Medical Officer
    Comp: $641.55k
  • Dr. Cassia Cearley Ph.D. (Age 41)
    Treasurer & Chief Business Officer
    Comp: $632.15k
  • Mr. Neil King Ph.D.
    Chair of Scientific Advisory Board & Co-Founder
  • Dr. David Baker M.D.
    Ph.D., Co-founder & Member of Scientific Advisory Board
  • Mr. Thomas Joseph Russo C.F.A. (Age 52)
    Chief Financial Officer
    Comp: $525.27k
  • Ms. Jennifer Raymond
    Senior Vice President of Technical Operations
  • Ms. Elizabeth Bekiroglu (Age 54)
    General Counsel & Corporate Secretary
    Comp: $230.74k
  • Ms. Lori Stewart
    Senior Vice President of People & Culture
  • Dr. Ami Shah Brown MPH
    Ph.D., Senior Vice President of Regulatory Affairs

ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares.
View ICVX analyst ratings
or view top-rated stocks.

What is Icosavax's stock price target for 2024?

3 brokers have issued 12 month price targets for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for ICVX
or view top-rated stocks among Wall Street analysts.

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to analyst estimates of $3.30 million.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

This page (NASDAQ:ICVX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners